SAN FRANCISCO, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, today announced the pricing of its upsized initial public offering of 21,250,000 shares of its common stock at a public offering price of $18.00 per share. The shares are expected to begin trading on the Nasdaq Global Market on August 6, 2026 under the ticker symbol “BRVE.” The offering is expected to close on August 7, 2026, subject to the satisfaction of customary closing conditions. All shares of common stock are being offered by Braveheart Bio.